MedPath

MVA.tHIVconsv4

Generic Name
MVA.tHIVconsv4

RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV

Phase 1
Not yet recruiting
Conditions
Acute HIV Infection
HIV Infections
PLWH
ART
Interventions
Biological: VRC07-523LS
Biological: PGDM1400LS
Other: Placebo
Biological: ChAdOx1.tHIVconsv1
Biological: ChAdOx1.HIVconsv62
Biological: MVA.tHIVconsv4
Biological: A244d11 gp120
Biological: ALFQ
First Posted Date
2024-07-03
Last Posted Date
2025-03-17
Lead Sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Target Recruit Count
48
Registration Number
NCT06484335
Locations
🇹🇭

The Faculty of Medicine, Chulalongkorn University/ King Chulalongkorn Memorial Hospital, Pathum Wan, Bangkok, Thailand

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

First Posted Date
2023-10-06
Last Posted Date
2025-04-25
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
45
Registration Number
NCT06071767
Locations
🇧🇷

Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS, Porto Alegre, Rio Grande Do Sul, Brazil

🇺🇸

University of California, San Diego AntiViral Research Center CRS, San Diego, California, United States

🇺🇸

Ponce de Leon Center CRS, Atlanta, Georgia, United States

and more 11 locations

Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3m4 in Persons With HIV-1 Suppressed on ART

Phase 1
Completed
Conditions
HIV Vaccine
HIV-1-infection
Interventions
Other: Placebo
Biological: C62
Biological: C1C62
Biological: M3M4
First Posted Date
2022-11-03
Last Posted Date
2025-04-09
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
18
Registration Number
NCT05604209
Locations
🇺🇸

University of North Carolina, Chapel Hill, North Carolina, United States

🇺🇸

Duke Human Vaccine Institute, Durham, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath